The M-gager® platform technology
The M-gager® platform is our proprietary technology for making highly specific and effective pMHC-targeting T cell engagers.
It is based on a unique phage display library with a repertoire of billions of antibodies already binding to the pMHC of interest.
The MHC-targeting M-gager® format results in effective and selective recruitment of T cells generating a specific cytotoxic T cell response against the cancer cell. The M-gager® molecules are expected to be highly effective immunotherapies for challenging but very attractive targets like neoantigens and cancer testis antigens with minimal off-tumor activity.
M-gager® molecules have excellent drug properties and are well-producible in standard mammalian cell-based manufacturing.